Manejo del Síndrome de Hiperestimulación Ovárica / Management of Ovarian Hyperstimulation Syndrome

INTRODUCCIÓN: El síndrome de hiperestimulación ovárica es una respuesta exagerada del ovario a los tratamientos hormonales para estimular la formación de óvulos. OBJETIVO: Describir el caso clínico de una mujer con síndrome de hiperestimulación ovárica; revisar el abordaje, manejo, tratamiento y cómo prevenirlo. CASO CLÍNICO: Paciente femenina de 37 años, multigesta, en tratamiento con metformina por Síndrome de ovario poliquístico , que presenta infertilidad secundaria a factor tubárico, que desarrolló un cuadro moderado de síndrome de hiperestimulación ovárica como consecuencia de la aplicación de las técnicas de fertilización in vitro (Folitropina alfa humana recombinante (GONAL-F®) y Cetrolerelix (CETROTIDE®); al cuarto día del procedimiento de aspiración folicular presenta dolor pélvico intenso, disuria, deposiciones diarreicas, ecografía abdominal y vaginal evidencia líquido libre en cavidad alrededor de 1000cc, además de ovarios tanto derecho e izquierdo con volumen de 102 mL y 189 mL respectivamente. Paciente es ingresada para realizar tratamiento hidratación parenteral, Enoxaparina 40mg subcutánea, Cabergolina 0.5mg vía oral, alta a las 72 horas. DISCUSIÓN: Las claves para la prevención del síndrome de hiperestimulación ovárica son la experiencia con la terapia de inducción de la ovulación y el reconocimiento de los factores de riesgo para el síndrome de hiperestimulación ovárica. Los regímenes de inducción de la ovulación deberían ser altamente individualizados, monitorizados cuidadosamente y usando dosis y duración mínimas del tratamiento con gonadotropinas para conseguir la meta terapéutica. CONCLUSIONES: El síndrome de hiperestimulación ovárica constituye la complicación más temida durante el uso de inductores de la ovulación; el conocimiento de factores de riesgo, puede prevenir o evitar que llegue a ser de un caso severo, lo cual puede causar mayor morbilidad o hasta mortalidad. La vitrificación se convierte en la técnica que permite prevenir el síndrome de hiperestimulación ovárica, junto con esta técnica hay 2 alternativas: la inducción con análogo de la hormona liberadora de gonadotropina o el uso de agonistas dopaminérgicos.

INTRODUCTION: Ovarian hyperstimulation syndrome is an exaggerated response of the ovary to hormonal treatments to stimulate egg formation. OBJECTIVE: To describe the clinical case of a woman with ovarian hyperstimulation syndrome; to review the approach, management, treatment and how to prevent it. CLINICAL CASE: 37-year-old female patient, multigestation, under treatment with metformin for polycystic ovary syndrome, presenting infertility secondary to tubal factor, who developed a moderate picture of ovarian hyperstimulation syndrome as a consequence of the application of in vitro fertilization techniques (recombinant human follitropin alfa (GONAL-F®) and Cetrolerelix (CETROTIDE®); On the fourth day of the follicular aspiration procedure she presents intense pelvic pain, dysuria, diarrheic stools, abdominal and vaginal ultrasound shows free fluid in the cavity of about 1000cc, in addition to right and left ovaries with a volume of 102 mL and 189 mL respectively. Patient was admitted for parenteral hydration treatment, Enoxaparin 40mg subcutaneous, Cabergoline 0.5mg orally, discharged after 72 hours. DISCUSSION: The keys to prevention of ovarian hyperstimulation syndrome are experience with ovulation induction therapy and recognition of risk factors for ovarian hyperstimulation syndrome. Ovulation induction regimens should be highly individualized, carefully monitored, and using minimal doses and duration of gonadotropin therapy to achieve the therapeutic goal. CONCLUSIONS: Ovarian hyperstimulation syndrome constitutes the most feared complication during the use of ovulation inducers; knowledge of risk factors, may prevent or avoid it from becoming a severe case, which may cause increased morbidity or even mortality. Vitrification becomes the technique that allows preventing ovarian hyperstimulation syndrome, along with this technique there are 2 alternatives: induction with gonadotropin-releasing hormone analog or the use of dopaminergic agonists.

Efficacy and safety of acupuncture for polycystic ovary syndrome: An overview of systematic reviews / 中西医结合学报

BACKGROUND@#Polycystic ovary syndrome (PCOS) is the primary cause of anovulatory infertility, bringing serious harm to women's physical and mental health. Acupuncture may be an effective treatment for PCOS. However, systematic reviews (SRs) on the efficacy and safety of acupuncture for PCOS have reported inconsistent results, and the quality of these studies has not been adequately assessed.@*OBJECTIVE@#To summarize and evaluate the current evidence on the efficacy and safety of acupuncture for PCOS, as well as to assess the quality and risks of bias of the available SRs.@*SEARCH STRATEGY@#Nine electronic databases (Cochrane Library, MEDLINE, Embase, PsycINFO, CINAHL, Chinese National Knowledge Infrastructure, Wanfang Data, Chongqing VIP Chinese Science and Technology Periodical Database, and China Biology Medicine disc) were searched from their establishment to July 27, 2022. Based on the principle of combining subject words with text words, the search strategy was constructed around search terms for "acupuncture," "polycystic ovary syndrome," and "systematic review."@*INCLUSION CRITERIA@#SRs of randomized controlled trials that explored the efficacy and (or) safety of acupuncture for treating patients with PCOS were included.@*DATA EXTRACTION AND ANALYSIS@#Two authors independently extracted study data according to a predesigned form. Tools for evaluating the methodological quality, risk of bias, reporting quality, and confidence in study outcomes, including A Measurement Tool to Assess Systematic Reviews 2 (AMSTAR 2), Risk of Bias in Systematic Reviews (ROBIS), Preferred Reporting Items for Systematic Reviews and Meta-analyses for Acupuncture (PRISMA-A), and the Grading of Recommendations Assessment, Development and Evaluation (GRADE), were used to score the included SRs.@*RESULTS@#A total of 885 studies were retrieved, and 11 eligible SRs were finally included in this review. The methodological quality of 2 SRs (18.18%) was low, while the other 9 SRs (81.82%) were scored as extremely low. Four SRs (36.36%) were considered to be of low risk of bias. As for reporting quality, the reporting completeness of 9 SRs (81.82%) was more than 70%. Concerning the confidence in study results, 2 study results were considered to have a high quality of evidence (3.13%), 14 (21.88%) a "moderate" quality, 28 (43.75%) a "low" quality, and 20 (31.24%) considered a "very low" quality. Descriptive analyses suggested that combining acupuncture with other medicines can effectively improve the clinical pregnancy rate (CPR) and ovulation rate, and reduce luteinizing hormone/follicle-stimulating hormone ratio, homeostasis model assessment of insulin resistance, and body mass index (BMI). When compared with medicine alone, acupuncture alone also can improve CPR. Further, when compared with no intervention, acupuncture had a better effect in promoting the recovery of menstrual cycle and reducing BMI. Acupuncture was reported to cause no adverse events or some adverse events without serious harm.@*CONCLUSION@#The efficacy and safety of acupuncture for PCOS remains uncertain due to the limitations and inconsistencies of current evidence. More high-quality studies are needed to support the use of acupuncture in PCOS.

Relationship between blood uric acid levels and body composition in patients with polycystic ovary syndrome / 中华妇产科杂志

Objective: To analyze the difference in blood uric acid levels between patients with polycystic ovary syndrome (PCOS) and healthy women of childbearing age, and to investigate the correlation between body composition and blood uric acid levels. Methods: A total of 153 eligible childbearing age patients with PCOS treated at Tianjin Medical University General Hospital from January 2018 to March 2022 were selected, and 153 healthy women with normal menstruation were selected as the control group. Fasting blood uric acid levels were measured by venous blood test, and body composition was measured by a body composition analyzer. Group comparisons were made to analyze the correlation between body composition and blood uric acid levels. Results: The incidence of hyperuricemia was higher in patients with PCOS than that in the control group [30.1% (46/153) vs 2.0% (3/153)], with a statistically significant difference (χ2=44.429, P<0.001). Blood uric acid level was also significantly higher in patients with PCOS than that in the control group [(371±98) vs (265±67) μmol/L; t=11.170, P<0.001]. Among PCOS patients, there were statistically significant differences in weight, body mass index (BMI), body fat mass, skeletal muscle mass, percent body fat, lean body weight, fat mass/lean body weight, percent skeletal muscle, and visceral fat level between the hyperuricemia group and the normal blood uric acid group (all P<0.001), but no significant difference was observed in waist-hip ratio (P=0.348). The following body composition indicators: weight, BMI, waist-hip ratio, body fat mass, skeletal muscle mass, percent body fat, visceral fat level, lean body weight, and fat mass/lean body weight in all subjects, the PCOS patients and the control group, were positively correlated with blood uric acid levels (all P<0.01). The blood uric acid level in PCOS obese patients was higher than that in non-obese PCOS patients, and the difference was statistically significant [(425±83) vs (336±91) μmol/L; t=6.133, P<0.001]. The blood uric acid level in central obesity PCOS patients was also higher than that in non-central obesity PCOS patients [(385±95) vs (299±79) μmol/L], the difference was statistically significant (t=4.261, P<0.001). The blood uric acid level in normal-weight obese PCOS patients was higher than that in normal-weight non-obese PCOS patients [(333±73) vs (277±54) μmol/L], and the difference was statistically significant (t=2.848, P=0.006). Blood uric acid levels in normal-weight [(315±74) vs (255±67) μmol/L], overweight [(362±102) vs (276±57) μmol/L], and obese PCOS patients [(425±83) vs (303±74) μmol/L] were all higher than those in the corresponding control groups, with statistically significant differences (all P<0.001). Conclusions: PCOS patients have a higher incidence of hyperuricemia than healthy women of childbearing age. Blood uric acid levels are closely correlated with body composition indicators, such as weight, BMI, waist-hip ratio, body fat mass, skeletal muscle mass, percent body fat, and visceral fat level. Body composition analysis of women with PCOS could help identify potentially obese people more accurately and carry out individualized treatment, thereby reducing the risk of metabolic abnormalities.

Attach great importance to the significance of serum anti-müllerian hormone and androgen in the evaluation of polycystic ovary syndrome / 中华预防医学杂志

Polycystic ovary syndrome (PCOS) is a common endocrine disease in women of childbearing age, which seriously affects women's reproductive health. In recent years, more and more studies have found that serum anti-Müllerian hormone (AMH) has certain significance in the diagnosis and treatment evaluation of PCOS. In addition, with the improvement of detection methods, more attention has been paid to the significance of female androgens and AMH in the evaluation of PCOS. This article reviews the recent research progress of serum AMH and androgens in the evaluation of PCOS.

Correlation analysis of vitamin D level and anti-Müllerian hormone in infertile female and the role in predicting pregnancy outcome / 北京大学学报(医学版)

OBJECTIVE@#To investigate the relationship between serum 25(OH)D and anti-Müllerian hormone (AMH) among infertile females and their predictive impacts on in vitro fertilization and embryo transfer pregnancy outcome.@*METHODS@#Totally 756 infertile females treated with assisted reproductive technology were enrolled and divided into three groups according to their vitamin D levels (group A with serum 25(OH)D≤10 μg/L, group B with serum (10-20) μg/L, and group C with serum ≥20 μg/L). The serum AMH levels were detected. The differences among the groups were analyzed, as well as the correlation between vitamin D levels and serum AMH levels in various infertility types (fallopian tube/male factor, polycystic ovary syndrome (PCOS), ovulation disorders excluded PCOS, endometriosis, unexplained infertility, and others). Also, the predictive roles of vitamin D and AMH in pregnancy outcome in all the infertile females were discussed.@*RESULTS@#(1) 87.7% of the enrolled females were insufficient or deficient in vitamin D. (2) The serum AMH levels in the three groups with different vitamin D levels were 1.960 (1.155, 3.655) μg/L, 2.455 (1.370, 4.403) μg/L, 2.360 (1.430, 4.780) μg/L and there was no significant difference in serum AMH levels among the three groups (P>0.05). (3) Serum 25(OH)D and AMH levels presented seasonal variations (P < 0.05). (4) There was no prominent correlation between the serum AMH level and serum 25(OH)D level in females of various infertility types after adjusting potential confounding factors [age, body mass index (BMI), antral follicle count (AFC), vitamin D blood collection season, etc.] by multiple linear regression analysis (P>0.05). (5) After adjusting for confounding factors, such as age, BMI, number of transplanted embryos and AFC, the results of binary Logistics regression model showed that in all the infertile females, the serum AMH level was an independent predictor of biochemical pregnancy outcome (P < 0.05) while the serum 25(OH)D level might not act as a prediction factor alone (P>0.05). In the meanwhile, the serum 25(OH)D level and serum AMH level were synergistic predictors of biochemical or clinical pregnancy outcome (P < 0.05).@*CONCLUSION@#Based on the current diagnostic criteria, most infertile females had vitamin D insufficiency or deficiency, but there was not significant correlation between serum 25(OH)D and ovarian reserve. While vitamin D could not be used as an independent predictor of pregnancy outcome in infertile females, the serum AMH level could predict biochemical pregnancy outcome independently or jointly with vitamin D.

Expression of PGRMC1 in patients with polycystic ovary syndrome and its molecular mechanism for regulating ovarian granulosa cell apoptosis and glucolipid metabolism / 中南大学学报(医学版)

OBJECTIVES@#Polycystic ovary syndrome (PCOS) is one of the most common endocrine diseases in women with reproductive age, which is associated with hyperandrogenism, insulin resistance, and ovulatory dysfunction. Progesterone receptor membrane component 1 (PGRMC1) can mediate progesterone to inhibit the apoptosis of ovarian granulosa cells and the growth of follicles, and to induce glucolipid metabolism disorder in ovarian granulosa cells, which is closely related to the occurrence and development of PCOS. This study aims to determine the expression of PGRMC1 in serum, ovarian tissue, ovarian granulosa cells, and follicular fluid in PCOS patients and non-PCOS patients, analyze the value of PGRMC1 in diagnosis and prognosis evaluation of PCOS, and investigate its molecular mechanism on ovarian granulosa cell apoptosis and glucolipid metabolism.@*METHODS@#A total of 123 patients were collected from the Department of Obstetrics and Gynecology in Guangdong Women and Children Hospital (hereinafter referred to as "our hospital") from August 2021 to March 2022 and divided into 3 groups: a PCOS pre-treatment group (n=42), a PCOS treatment group (n=36), and a control group (n=45). The level of PGRMC1 in serum was detected by enzyme linked immunosorbent assay (ELISA). The diagnostic and prognostic value of PGRMC1 was evaluated in patients with PCOS by receiver operating characteristic (ROC) curve. Sixty patients who underwent a laparoscopic surgery from the Department of Obstetrics and Gynecology in our hospital from January 2014 to December 2016 were collected and divided into a PCOS group and a control group (n=30). The expression and distribution of PGRMC1 protein in ovarian tissues were detected by immunohistochemical staining. Twenty-two patients were collected from Reproductive Medicine Center in our hospital from December 2020 to March 2021, and they divided into a PCOS group and a control group (n=11). ELISA was used to detect the level of PGRMC1 in follicular fluid; real-time RT-PCR was used to detect the expression level of PGRMC1 mRNA in ovarian granulosa cells. Human ovarian granular cell line KGN cells were divided into a scrambled group which was transfected with small interfering RNA (siRNA) without interference and a siPGRMC1 group which was transfected with specific siRNA targeting PGRMC1. The apoptotic rate of KGN cells was detected by flow cytometry. The mRNA expression levels of PGRMC1, insulin receptor (INSR), glucose transporter 4 (GLUT4), very low density lipoprotein receptor (VLDLR), and low density lipoprotein receptor (LDLR) were determined by real-time RT-PCR.@*RESULTS@#The serum level of PGRMC1 in the PCOS pre-treatment group was significantly higher than that in the control group (P<0.001), and the serum level of PGRMC1 in the PCOS treatment group was significantly lower than that in the PCOS pre-treatment group (P<0.001). The areas under curve (AUC) of PGRMC1 for the diagnosing and prognosis evaluation of PCOS were 0.923 and 0.893, respectively, and the cut-off values were 620.32 and 814.70 pg/mL, respectively. The positive staining was observed on both ovarian granulosa cells and ovarian stroma, which the staining was deepest in the ovarian granulosa cells. The average optical density of PGRMC1 in the PCOS group was significantly increased in ovarian tissue and ovarian granulosa cells than that in the control group (both P<0.05). Compared with the control group, the PGRMC1 expression levels in ovarian granulosa cells and follicular fluid in the PCOS group were significantly up-regulated (P<0.001 and P<0.01, respectively). Compared with the scrambled group, the apoptotic rate of ovarian granulosa cells was significantly increased in the siPGRMC1 group (P<0.01), the mRNA expression levels of PGRMC1 and INSR in the siPGRMC1 group were significantly down-regulated (P<0.001 and P<0.05, respectively), and the mRNA expression levels of GLUT4, VLDLR and LDLR were significantly up-regulated (all P<0.05).@*CONCLUSIONS@#Serum level of PGRMC1 is increased in PCOS patients, and decreased after standard treatment. PGRMC1 could be used as molecular marker for diagnosis and prognosis evaluation of PCOS. PGRMC1 mainly localizes in ovarian granulosa cells and might play a key role in regulating ovarian granulosa cell apoptosis and glycolipid metabolism.

Riscos de infecção por SARS-CoV-2 e COVID-19 em mulheres com síndrome dos ovários policísticos / Risks of SARS-CoV-2 and COVID-19 infection in women with polycystic ovary syndrome

Esta revisão narrativa teve como objetivo avaliar possíveis riscos da associação entre a infecção por SARS-CoV-2 (causa da COVID-19) e as características metabólicas e endócrinas frequentemente encontradas em mulheres com a síndrome dos ovários policísticos (SOP). A COVID-19 é mais grave em indivíduos com obesidade, diabetes mellitus, dislipidemia e hipertensão arterial. Como essas condições são comorbidades comumente associadas à SOP, foi hipotetizado que mulheres com SOP teriam maior risco de adquirir COVID-19 e desenvolver formas clínicas mais graves da doença. Considerando vários estudos epidemiológicos, a presente revisão mostra que mulheres com SOP têm risco 28% a 50% maior de serem infectadas pelo vírus SARS-CoV-2 em todas as idades e que, nessas mulheres, a COVID-19 está associada a maiores taxas de hospitalização, morbidade e mortalidade, especialmente naquelas com alterações no metabolismo de carboidratos e lipídios, hiperandrogenemia e aumento do tecido adiposo visceral. Os mecanismos que explicam o maior risco de infecção por COVID-19 em mulheres com SOP são considerados.(AU)

Avances en la genética del síndrome de ovario poliquístico

Introducción: Los primeros estudios realizados en familiares de mujeres con síndrome de ovario poliquístico demostraron un patrón de agregación familiar y por tanto, la posibilidad de un componente genético en su etiopatogenia. Desde entonces, mucho se ha investigado al respecto. Objetivo: Realizar una actualización en las evidencias según la literatura de las bases genéticas del síndrome de ovario poliquístico. Métodos: Se realizó una revisión bibliográfica de los últimos 10 años sobre aspectos de genética en el síndrome de ovario poliquístico en las bases Pubmed, Google Académico, EMBASE y MEDLINE. Conclusiones: Se demostró que en este periodo se ha avanzado en el esclarecimiento y participación de múltiples genes y loci en la patogenia del síndrome. Existe una asociación importante en diferentes poblaciones y etnias del gen DENND1A y TADHA, los cuales se localizan en los cromosomas 9 y 2, respectivamente. Además, se han realizado estudios de asociación del genoma completo (GWAS) que han identificado otros genes en cromosomas como 9q22.32, 11q22.1, 12q13.2, 19p13.3, 16 q12.1, 20q13.2, 12q14.3 (C9orf3, YAP1, RAB5B, INSR, TOX3, SUMO1P1 y HMGA2). Esta revisión permite una actualización del tema y ampliar el conocimiento sobre aspectos relacionados con el origen genético del SOP, así como concluir que el SOP tiene un origen poligénico y es de las denominadas enfermedades complejas(AU)

Introduction: Early studies in relatives of women with polycystic ovary syndrome demonstrated a pattern of familial aggregation and thus the possibility of a genetic component in its etiopathogenesis. Since then, much research has been done on this subject. Objective: To update the evidence according to the literature on the genetic basis of polycystic ovary syndrome. Methods: A literature review of the last 10 years on genetic aspects of polycystic ovary syndrome was performed in Pubmed, Google Scholar, EMBASE and MEDLINE databases. Conclusions: It was shown that in this period progress has been made in the elucidation and involvement of multiple genes and loci in the pathogenesis of the syndrome. There is a significant association in different populations and ethnicities of the DENND1A and TADHA gene, which are located on chromosomes 9 and 2, respectively. In addition, genome-wide association studies (GWAS) have been performed and have identified other genes on chromosomes such as 9q22.32, 11q22.1, 12q13.2, 19p13.3, 16 q12.1, 20q13.2, 12q14.3 (C9orf3, YAP1, RAB5B, INSR, TOX3, SUMO1P1 and HMGA2). This review allows an update of the subject and to expand the knowledge on aspects related to the genetic origin of PCOS, as well as to conclude that PCOS has a polygenic origin and is one of the so-called complex diseases(AU)

Ansiedad y depresión en mujeres con el síndrome de ovario poliquístico / Anxiety and depression in women with polycystic ovary syndrome

Introducción: El síndrome de ovario poliquístico es una condición muy frecuente en la mujer durante la etapa fértil y tiene implicaciones en la esfera reproductiva y cardiometabólica. Sin embargo, se ha observado que estas mujeres también pueden ver afectada su esfera psicoafectiva. Objetivo: Demostrar que las mujeres con síndrome de ovario poliquístico tienen mayor frecuencia de padecer alteraciones del ánimo (ansiedad y depresión). Métodos: Con la metodología de la investigación documental se analizaron 54 artículos publicados desde 2002, procedentes de las bases de PubMed/MEDLINE, Embase, PsycINFO and Web. Se usaron como palabras clave: síndrome de ovario poliquístico, ansiedad, depresión, alteraciones psicológicas y alteraciones psicoafectivas. Conclusiones: Los resultados de las investigaciones revisadas coinciden en que las mujeres con síndrome de ovario poliquístico tienen niveles más latos de depresión y ansiedad que las mujeres sin el síndrome, lo cual se basa en mecanismos biológicos y socioculturales(AU)

Introduction: Polycystic ovary syndrome is a very frequent condition in women during the fertile stage and has reproductive and cardiometabolic implications. However, it has been observed that these women may also be affected in their psychoaffective sphere. Objective: To demonstrate that women with polycystic ovary syndrome have a higher frequency of mood disorders (anxiety and depression). Methods: Using documentary research methodology, 54 articles published since 2002 were analyzed from PubMed/MEDLINE, Embase, PsycINFO and Web databases. Polycystic ovary syndrome, anxiety, depression, psychological alterations and psychoaffective alterations were used as keywords. Conclusions: The results of the reviewed research coincide in demonstrating that women with PCOS have lower levels of depression and anxiety than women without the syndrome which is based on biological and sociocultural mechanisms(AU)

Síndrome de ovario poliquístico y calidad de vida

Introducción: El síndrome de ovario poliquístico es la endocrinopatía más frecuente que afecta la mujer en la etapa reproductiva. Se ha investigado mucho en lo que concierne a su fisiopatología y criterios diagnósticos. Sin embargo, existen evidencias de que las mujeres que padecen el síndrome tienen mayor afectación en su calidad de vida. El tema ha sido poco abordado en general y en Cuba no existen estudios al respecto. Objetivo: Identificar las evidencias científicas que amplíen el conocimiento acerca del efecto del síndrome de ovario poliquístico en la calidad de vida. Métodos: Se realizó una revisión bibliográfica sobre la calidad de vida en mujeres con diagnóstico de síndrome de ovario poliquístico. La búsqueda se realizó en las bases de datos electrónicas Google Scholar, Pubmed Central y SCIELO Regional, a las cuales se accedió por medio del buscador web de Google. Se revisaron artículos completos, relacionados con estudios observacionales, prospectivos, artículos de revisión, revisiones sistemáticas y metaanálisis publicados fundamentalmente entre 2000 y 2020. Conclusiones: La presente revisión pone en evidencia que el síndrome de ovario poliquístico es una condición que por la variedad de manifestaciones clínicas que lo caracterizan conlleva a un deterioro de la calidad de vida de las mujeres que la padecen. Una intervención terapéutica en cada una de ellas resulta beneficiosa para elevar el bienestar físico y psicológico y como resultado de la calidad de vida(AU)

Introduction: Polycystic ovary syndrome is the most common endocrinopathy affecting women in the reproductive stage. Much research has been done regarding its pathophysiology and diagnostic criteria. However, there is evidence that women who suffer from the syndrome have greater negative effects in their quality of life. The subject has not been amply approached in general and there are no studies on the subject in Cuba. Objective: To identify the scientific evidence that broadens knowledge about the effect of polycystic ovary syndrome on quality of life. Methods: A bibliographic review was carried out on the quality of life in women diagnosed with polycystic ovary syndrome. The search was performed in the electronic databases Google Scholar, Pubmed central and SCIELO Regional, which were accessed through the Google web search engine. Full articles related to observational studies, prospective studies, review articles, systematic reviews and meta-analyses, published mainly between 2000 and 2020, were reviewed. Conclusions: The present review highlights that PCOS is a condition that, due to the variety of clinical manifestations that characterize it, leads to a deterioration in the quality of life of women who suffer from it. A therapeutic intervention in each of them is beneficial to improve physical and psychological well-being and as a result, quality of life(AU)

La metformina durante el embarazo en mujeres con síndrome de ovario poliquístico / Metformin during pregnancy in women with polycystic ovary syndrome

Introducción: La resistencia a la insulina tiene gran relevancia en la patogenia del síndrome de ovario poliquístico, por lo que es común que se empleen los sensibilizadores a la insulina. La metformina tiene diversos fines terapéuticos y es la más recomendada. Durante el embarazo desempeña un rol en la reducción del riesgo de aborto, la hipertensión inducida por el embarazo, la macrosomía, la cesárea y la hipoglucemia neonatal. Con resultados menos consistentes también participa en la reducción del riesgo de diabetes gestacional. No obstante, existen preocupaciones sobre su seguridad a largo plazo. Objetivo: Realizar una actualización del estado del arte sobre el empleo de la metformina durante el embarazo en mujeres con síndrome de ovario poliquístico. Métodos: Se realizó una revisión bibliográfica donde se consultaron 57 artículos obtenidos de las bases de datos Google Académico, Medline, Pubmed, SciELO. Conclusiones: El tratamiento con metformina es más fácil, más económico y menos "inquietante" que la insulina. La prescripción y adherencia son más simples, lo que ha contribuido a que en la práctica clínica se emplee la metformina durante el embarazo con una frecuencia cada vez mayor. El posicionamiento actual de la comunidad científica acepta la metformina como una alternativa válida de tratamiento en las mujeres con síndrome de ovario poliquístico durante el embarazo pero recomienda poner cuidado en la observación de su seguridad a largo plazo e incrementar la evidencia(AU)

Introduction: Insulin resistance is highly relevant in the pathogenesis of polycystic ovary syndrome, which is why it is common to use insulin sensitizers. Metformin has various therapeutic purposes and is the most recommended. During pregnancy, it plays a role in reducing the risk of miscarriage, pregnancy-induced hypertension, macrosomia, cesarean section, and neonatal hypoglycemia. With less consistent results, it also participates in reducing the risk of gestational diabetes. However, there are concerns about its long-term safety. Objective: To update the state of the art on the use of metformin during pregnancy in women with polycystic ovary syndrome. Methods: A bibliographic review was carried out where 57 articles obtained from the Google Scholar, Medline, Pubmed, SciELO databases were consulted. Conclusions: Treatment with metformin is easier, cheaper and less "disturbing" than insulin. Prescription and adherence are simpler, which has contributed to the fact that metformin is used in clinical practice during pregnancy with increasing frequency. The current position of the scientific community accepts metformin as a valid treatment alternative in women with polycystic ovary syndrome during pregnancy, but recommends careful observation of its long-term safety and increasing evidence(AU)

La hormona antimulleriana y el síndrome de ovario poliquístico / Antimullerian hormone and polycystic ovary syndrome

Introducción: El diagnóstico del síndrome de ovario poliquístico, por su gran diversidad fenotípica ha sido y es objeto de debate. Es en este contexto que en los últimos años se ha propuesto la medición de la hormona antimulleriana como un indicador más eficaz en la evaluación de la disfunción folicular. Objetivo: Compilar información sobre la hormona antimulleriana y su utilidad diagnóstica en el síndrome de ovario poliquístico. Métodos: Revisión bibliográfica de 57 artículos obtenidos de las bases de datos Google Académico, Medline y Pubmed. Conclusiones: La concentración intrafolicular de hormona antimulleriana es inversamente proporcional al tamaño del folículo ovárico y sus niveles séricos son proporcionales a la reserva de folículos en estadio preantral o antral pequeño. En mujeres con síndrome de ovario poliquístico se ha observado incremento de hormona antimulleriana que se cree juega un papel en la patogenia de las alteraciones de la foliculogénesis y la disfunción ovárica. Por ello, la determinación de hormona antimulleriana se ha empleado con fines diagnósticos, como indicador de reserva folicular o como predictor de la respuesta a los tratamientos. Sin embargo, las dificultades técnicas para la medición y la variabilidad poblacional e interindividual, han llevado a que su utilidad práctica para el diagnóstico del síndrome de ovario poliquístico no haya podido establecerse consistentemente(AU)

Introduction: The diagnosis of polycystic ovary syndrome, due to its great phenotypic diversity, has been and is the subject of debate. It is in this context that in recent years the measurement of anti-Müllerian hormone has been proposed as a more effective indicator in the evaluation of follicular dysfunction. Objective: Compile information on the antimullerian hormone and its diagnostic utility in polycystic ovary syndrome. Methods: Bibliographic review of 57 articles obtained from the Google Scholar, Medline and Pubmed databases. Conclusions: The intrafollicular concentration of anti-Müllerian hormone is inversely proportional to the size of the ovarian follicle and its serum levels are proportional to the reserve of follicles in the preantral or small antral stage. An increase in anti-Müllerian hormone has been observed in women with polycystic ovary syndrome, which is believed to play a role in the pathogenesis of abnormal folliculogenesis and ovarian dysfunction. For this reason, the determination of anti-Müllerian hormone has been used for diagnostic purposes, as an indicator of follicular reserve or as a predictor of response to treatment. However, the technical difficulties for the measurement and the population and inter-individual variability have meant that its practical utility for the diagnosis of polycystic ovary syndrome has not been consistently established(AU)

La función sexual y su relación con los factores psicológicos en las mujeres con el síndrome de ovario poliquístico / Sexual function and its relationship to psychological factors in women with polycystic ovary syndrome

Introducción: El síndrome de ovario poliquístico tiene un notable impacto en la vida de las personas que lo padecen, siendo las áreas psicológica y sexual frecuentemente afectadas. Objetivos: Realizar una revisión bibliográfica sobre la función sexual y su relación con factores psicológicos en mujeres con síndrome de ovario poliquístico. Métodos: Se revisaron las bases de datos Google Scholar, Pubmed Central y SciELO Regional por intermedio del buscador web de Google. Algunos de los aspectos tratados en el artículo fueron los factores psicológicos, las hormonas sexuales y la función sexual, la imagen corporal y el síndrome de ovario poliquístico, y la función sexual y el síndrome de ovario poliquístico. Conclusiones: Los aspectos más estudiados del síndrome de ovario poliquístico han estado relacionados con la conceptualización y fisiopatología de la enfermedad, y las manifestaciones reproductivas y metabólicas. Otros aspectos igualmente importantes como los psicosociales y sexuales han sido muy escasamente abordados y los datos disponibles son contradictorios. Se requieren investigaciones de corte psicosocial para profundizar en las particularidades de la vida psicoemocional y sexual de esta población. Aún existe un campo novedoso poco explorado y permanecen vacíos de información en torno a la sexualidad que por su impacto influyen en el bienestar psicológico y la calidad de vida(AU)

Introduction: Polycystic ovary syndrome has a notable impact on the lives of those who suffer from it, with the psychological and sexual areas frequently affected. Objective: To carry out a literature review on sexual function and its relationship with psychological factors in women with polycystic ovary syndrome. Methods: Google Scholar, Pubmed Central and SciELO Regional databases were reviewed through the Google web search engine. Some of the aspects covered in the article were psychological factors, sex hormones and sexual function, body image and polycystic ovary syndrome, and sexual function and polycystic ovary syndrome. Conclusions: The reviewed literature allows affirming that in the Cuban and international context the most studied aspects of polycystic ovary syndrome have been related to the conceptualization and physiopathology of the disease, and its reproductive and metabolic manifestations. Other equally important aspects such as psychosocial and sexual aspects have been very scarcely broached and the available information is contradictory. Psychosocial research is needed to delve deeper into the particularities of the psychoemotional and sexual life of this population. There is still a novel field that has not been sufficiently explored and there are still gaps in the information on sexuality that, due to their impact, influence the psychological well-being and the patients' quality of life(AU)

Fisiopatología del síndrome de ovario poliquístico / Pathophysiology of polycystic ovary syndrome

Introducción: En la génesis del síndrome de ovario poliquístico intervienen múltiples factores sistémicos y locales que tienen una relación multidireccional sobre los que persisten muchas cuestiones aún sin dilucidar y cierta confusión e incertidumbre. Objetivo: Describir el enfoque actual sobre las causas y los mecanismos involucrados en el origen y desarrollo del síndrome de ovario poliquístico. Métodos: Se realizó una revisión bibliográfica tipo estado del arte. Se revisaron alrededor de 250 artículos, que se obtuvieron de las bases PubMed, Medline, SciELO y Google Académico. Se describen los factores y las vías que se proponen para explicar la etiopatogenia y fisiopatología de alteraciones genéticas, ambientales, endocrinas y metabólicas asociadas al síndrome y su expresión clínica. Conclusiones: La fisiopatología del síndrome de ovario poliquístico es compleja. Muchos aspectos permanecen sin esclarecerse, pero se tiene cada vez más conocimiento que aporta luz a los enigmas que aún persisten y a la comprensión de fenómenos previamente desconocidos. Existe el convencimiento creciente de que la alteración central es a nivel ovárico, que el síndrome es heterogéneo en todos sus elementos y que conocer la gran diversidad de factores y mecanismos que intervienen en su etiología y patogenia es fundamental no sólo desde lo científico, sino también por su utilidad práctica(AU)

Introduction: Multiple systemic and local factors are involved in the genesis of polycystic ovary syndrome that have a multidirectional relationship about which many there are questions yet to be clarified and some confusion and uncertainty persist. Objective: To describe the current approach to the causes and mechanisms involved in the origin and development of polycystic ovary syndrome. Methods: A state-of-the-art literature review was performed. The factors and pathways proposed to explain the etiopathogenesis and pathophysiology of genetic, environmental, endocrine and metabolic alterations associated with the syndrome and its clinical expression are described. Conclusions: The pathophysiology of polycystic ovary syndrome is complex. Many aspects remain unclear, but there is increasing knowledge that sheds light on the enigmas that still persist and on the understanding of previously unknown phenomena. There is a growing conviction that the central alteration is at the ovarian level, that the syndrome is heterogeneous in all its elements and that knowledge of the great diversity of factors and mechanisms involved is fundamental, not only from the scientific point of view but also for its practical utility(AU)

Particularidades de la resistencia a la insulina en el síndrome de ovario poliquístico / Particularities of insulin resistance in polycystic ovary syndrome

Introducción: La resistencia a la insulina e hiperinsulinemia son frecuentes en las mujeres con síndrome de ovario poliquístico. Una condición que resulta relevante como factor patogénico principal de las alteraciones metabólicas que acompañan al síndrome y porque condiciona fenotipos con mayor riesgo metabólico y reproductivo. Objetivo: Realizar una revisión bibliográfica sobre la resistencia a la insulina en el síndrome de ovario poliquístico. Métodos: Se realizó una revisión bibliográfica tipo estado del arte. Se consultaron 229 artículos obtenidos de las bases PubMed, Medline, SciELO y Google Académico. Conclusiones: La resistencia a la insulina tiene importancia capital en el síndrome de ovario poliquístico, no sólo por su frecuencia, sino también por el amplio espectro de alteraciones metabólicas y reproductivas que se le asocian. Como en otros trastornos que caracterizan al síndrome, los mecanismos fisiopatogénicos específicos no están del todo claros, pero existe la posibilidad de diagnosticarla y tratarla oportunamente, con lo que pueden prevenirse complicaciones, algunas de importancia vital. Por esto, la educación para la salud desde edades tempranas, que propicie estilos de vida saludable, prevención del sobrepeso corporal y control de otros factores que agravan la resistencia a la insulina, así como la evaluación temprana de la resistencia a la insulina, deben entenderse como cruciales en el manejo de las mujeres con síndrome de ovario poliquístico, con independencia de su peso corporal(AU)

Introduction: Insulin resistance and hyperinsulinemia are frequent in women with polycystic ovary syndrome. This condition is relevant as the main pathogenic factor of the metabolic alterations that accompany the syndrome and because it conditions phenotypes with higher metabolic and reproductive risk. Objective: To perform a literature review on insulin resistance in polycystic ovary syndrome. Methods: A state-of-the-art literature review was performed. The particularities of insulin resistance associated with the syndrome and its clinical expression are described. Conclusions: Insulin resistance is of paramount importance in polycystic ovary syndrome, not only because of its frequency, but also because of the wide spectrum of metabolic and reproductive alterations associated with it. As in other disorders that characterize the syndrome, the specific pathophysiological mechanisms are not entirely clear. However, it is possible to diagnose and treat it in a timely manner, thus preventing complications, some of which are of vital importance. Therefore, and regardless of their body weight, health education from an early age to promote healthy lifestyles, prevention of body overweight and control of other factors that aggravate insulin resistance, including early evaluation of insulin resistance, should be understood as crucial in the management of women with polycystic ovary syndrome(AU)

Mitos y realidades sobre la obesidad en el síndrome de ovario poliquístico / Myths and realities about obesity in polycystic ovary syndrome

Introducción: La asociación entre la obesidad y el síndrome de ovario poliquístico es importante porque amplifica los trastornos metabólicos, reproductivos, psicológicos o de la calidad de vida. Sin embargo, es común que se sobrevalore o se emplee como criterio diagnóstico, lo que denota una definición no clara de esta relación. Objetivo: Analizar lo que, en opinión de los autores, pudieran ser "mitos" sobre la obesidad en el síndrome de ovario poliquístico y su coherencia con la evidencia disponible. Métodos: Se realizó una revisión del estado del arte en este tema. Se localizaron 230 artículos en las bases PubMed, Medline, Scielo y Google Académico, y se contrastó con los criterios propios. Conclusiones: Algunas creencias generalizadas sobre la obesidad en el síndrome de ovario poliquístico, aunque tienen cierto grado de certidumbre, se malinterpretan o magnifican, por lo que pueden considerarse "mitos". Entender que las mujeres con síndrome de ovario poliquístico pueden no tener obesidad y, aún así, tener adiposidad abdominal y los efectos que de ella derivan, no niega la evidencia indiscutible de que la obesidad, si está presente, agrava el síndrome. Polemizar sobre el tema pretende contribuir a que se diagnostique el síndrome no solo en mujeres con obesidad y que se considere factor de riesgo para la obesidad. Debe entenderse que la obesidad asociada al síndrome puede revertirse y que se pueden incorporar estilos de vida saludable y un control del peso corporal como pilares del tratamiento en todas las mujeres que padezcan este(AU)

Introduction: The association between obesity and polycystic ovary syndrome is important because it amplifies metabolic, reproductive, psychological, or quality of life disorders. However, it is commonly overestimated or used as a diagnostic criterion, which denotes an unclear definition of this relationship. Objective: To analyze what, in the authors' opinion, could be "myths" about obesity in polycystic ovary syndrome and their consistency with the available evidence. Methods: A state-of-the-art review on this subject was performed and contrasted with own criteria. Conclusions: Some widespread beliefs about obesity in polycystic ovary syndrome, although they have some degree of certainty, are misinterpreted or magnified, so they can be considered "myths". Understanding that the patients may not suffer from obesity and still have abdominal adiposity and the effects that derive from it, does not deny the indisputable evidence that, if present, it aggravates the syndrome. Discussing the subject intends to contribute to diagnose the syndrome not only in women with obesity. The aim is to consider it as a risk factor for obesity and to prevent it, to understand that obesity can be reversed, and to incorporate counseling on healthy lifestyles and body weight control as pillars of treatment in all women with the syndrome, with or without obesity(AU)

Diagnóstico hormonal del síndrome de ovario poliquístico / Hormonal diagnosis of polycystic ovary syndrome

Introducción: El síndrome de ovario poliquístico es el trastorno endocrino más frecuente en la mujer durante la etapa reproductiva. Se han realizado varios consensos con el fin de definir sus criterios diagnósticos y el hiperandrogenismo siempre ha estado presente dentro, ya sea tipo clínico o humoral. Objetivo: Describir los aspectos relacionados con el diagnostico hormonal en el síndrome de ovario poliquístico. Métodos: Se realizó una revisión bibliográfica sobre aspectos relacionados con el diagnóstico hormonal del síndrome de ovario poliquístico. Se obtuvieron artículos originales en inglés de las bases Pubmed, Google académico, EMBASE y MEDLINE. Se priorizó el término que aparece en el MESH BROWSER de síndrome de ovario poliquístico. Conclusiones: El diagnostico hormonal del síndrome de ovario poliquístico debe demostrar el hiperandrogenismo de manera bioquímica, siempre que sea posible, aunque si existe evidencia clínica basada en los propios criterios diagnósticos no es obligatorio. El método de laboratorio más útil al parecer es la determinación de la testosterona libre o en su lugar el del índice de andrógenos libres, seguido de la testosterona total. Otras determinaciones de andrógenos tienen menos valor como primera línea(AU)

Introduction: Polycystic ovary syndrome is the most common endocrine disorder in women during the reproductive stage. Several consensuses have been made in order to define its diagnostic criteria and hyperandrogenism has always been present, either clinical or mood related. Objective: To describe the aspects related to hormonal diagnosis in polycystic ovary syndrome. Methods: A literature review was performed on aspects related to the hormonal diagnosis of polycystic ovary syndrome. Original articles in English were obtained from Pubmed, Google Scholar, EMBASE and MEDLINE databases. Priority was given to the MESH BROWSER term polycystic ovary syndrome. Results: The hormonal diagnosis of polycystic ovary syndrome should demonstrate hyperandrogenism biochemically, whenever possible, although if there is clinical evidence based on the diagnostic criteria themselves it is not mandatory. The most useful laboratory method appears to be the determination of free testosterone or instead that of the free androgen index, followed by total testosterone. Other androgen determinations are of less value as first line(AU)

Variabilidad clínica del síndrome de ovario poliquístico / Clinical variability in polycystic ovary syndrome

Introducción: El síndrome de ovario poliquístico es la forma más común de anovulación crónica relacionada con exceso de andrógenos. La prevalencia oscila según el criterio diagnóstico utilizado entre 4-21 pòr ciento. Objetivo: Describir las características clínicas de las pacientes con síndrome de ovario poliquístico. Métodos: Se seleccionaron los consensos hasta ahora realizados y artículos originales de los último 10 años, disponibles en los siguientes buscadores: Pubmed, Medscape, Scielo, Bireme. Se consideraron otras publicaciones que por su importancia clínica no han sido replicados. Conclusiones: La variedad de fenotipos presentes en el SOP hace que las manifestaciones clínicas y factores de riesgo para otras morbilidades sean heterogéneas. La influencia que ejerce además su etiopatogenia, no completamente dilucidada, hace que el diagnóstico y por consiguiente el manejo actual de estas pacientes tenga un enfoque multidisciplinario, individualizado y enfocado a las prioridades e inconformidades que puedan afectar su calidad de vida(AU)

Introduction: Polycystic ovary syndrome (PCOS) is the most common form of chronic anovulation related to androgen excess. The prevalence ranges according to the diagnostic criteria used between 4-21 percent. Objective: To describe the clinical characteristics of patients with polycystic ovary syndrome. Methods: The consensuses and original articles of the last 10 years were selected, which were available in the following search engines: Pubmed, Medscape, Scielo, and Bireme. Other publications that due to their clinical importance have not been replicated were considered. Conclusions: The variety of phenotypes present in the polycystic ovary syndrome makes the clinical manifestations and risk factors for other morbidities heterogeneous. The influence exerted also by its etiopathogenesis, not completely elucidated, causes the diagnosis and therefore the current management of these patients to have a multidisciplinary approach which is individualized and focused on the priorities and nonconformities that may affect the patients' quality of life(AU)

Prevalencia de síndrome de ovario poliquístico en pacientes que acudieron a una consulta de ginecología-obstetricia y endocrinología en La Romana, República Dominicana, durante el período enero 2019-enero 2020 / Prevalence of polycystic ovary syndrome in patients who attended a gynecology-obstetrics and endocrinology private practice in La Romana, Dominican Republic during the period January 2019-January 2020

Introducción: el síndrome de ovario poliquístico (SOP) es un trastorno endocrino metabólico altamente dominante, el cual es considerado como una de las afecciones más comunes en las mujeres, tanto adolescentes como adultas durante su etapa fértil. Presenta una prevalencia de aproximadamente un 21 % a nivel global. Objetivo: determinar la prevalencia del síndrome de ovario poliquístico en pacientes que acudieron a una consulta de ginecología-obstetricia y endocrinología en la Romana, República Dominicana. Metodología: estudio observacional, retrospectivo, analítico y de corte transversal en el que se analizaron 252 récords médicos de distintas pacientes con y sin SOP para determinar la prevalencia de esta. Como herramienta de estudio se utilizó un formulario creado por el asesor y colaboradores, que se aplicó a los récords médicos empleando los criterios de Rotterdam como determinantes para el diagnóstico del SOP. Resultados: los resultados mostraron que un 67 % de las mujeres no presentaron SOP, correspondiendo a 170 pacientes, mientras que las 82 pacientes restantes presentaron SOP, representando un 33 %. Asimismo, el grupo etario con mayor frecuencia de SOP correspondió al rango de 26 a 35 años con un 52.4 %. Por otra parte, se presentaron más pacientes con SOP no obesas con un 71 %. Con relación a la presencia de ciclos menstruales regulares e irregulares, las pacientes irregulares con SOP indicaron un 47.6 % y las pacientes regulares sin SOP indicaron un 16.7 %, resultando que se acepta la hipótesis nula. Conclusiones: la prevalencia de síndrome de ovario poliquístico fue de un 33 %. El rango de edad más frecuente fue de 26 a 35 años. Predominó la presencia de pacientes con SOP no obesas. La comparación de las pacientes con ciclos menstruales irregulares fue mayor para aquellas que padecen SOP

Introduction: Polycystic ovary syndrome (PCOS) is a highly dominant endocrine metabolic disorder, which is considered one of the most common conditions in women, both adolescents and adults during their fertile stage. It has a prevalence of approximately 21% globally. Objectives: To determine the prevalence of polycystic ovary syndrome in patients who attended a gynecology-obstetrics and endocrinology consultation in la Romana, Dominican Republic. Methodology: An observational, retrospective, analytical and cross-sectional study in which 252 medical records of different patients with and without PCOS were analyzed to determine its prevalence. As a study tool, a form created by the advisor and collaborators was used, which was applied to medical records, the Rotterdam criteria were employed as determinants for the diagnosis of PCOS. Results: The results showed that 67% of the women did not present PCOS corresponding to 170 patients, while the remaining 82 patients presented PCOS representing 33%. Likewise, the age group with the highest frequency of PCOS corresponded to the range of 26 to 35 years with 52.4%. On the other hand, there were more non-obese PCOS patients with 71%. Regarding the presence of regular and irregular menstrual cycles, irregular patients with PCOS indicated 47.6% and regular patients without PCOS indicated 16.7%, resulting in the acceptance of the null hypothesis. Conclusions: The prevalence of polycystic ovary syndrome was 33%. The most frequent age range was 26 to 35 years. The presence of non-obese PCOS patients predominated. The comparison of patients with irregular menstrual cycles was higher for those with PCOS

Polycystic Ovary Syndrome in Adolescence: Challenges in Diagnosis and Management / Síndrome do ovário policístico na adolescência: Desafios no diagnóstico e tratamento

Abstract Diagnosing polycystic ovary syndrome (PCOS) during adolescence is challenging since normal pubertal development overlap typical features of this syndrome. The authors aim to summarize the existing evidence concerning PCOS in adolescence, particularly its diagnostic criteria and therapeutic options. A search throughout medical databases such as PubMed and MedScape was performed. Diagnostic criteria include irregular menstrual cycles according to time postmenarche and evidence of clinical hyperandrogenism and/or biochemical hyperandrogenism, provided other causes have been excluded. Polycystic ovarianmorphology ought not to be used as a diagnostic criterion. Treatment should targetmanifestations and/or comorbidities, even in the absence of a definite diagnosis. Lifestyle interventions are the first-line treatment. Combined oral contraceptives, metformin or antiandrogens may also be considered as adjuvants. Screening for PCOS in adolescence is crucial as it allows an early intervention on the symptoms and comorbidities presented leading to better long-term reproductive and metabolic outcomes.

Resumo Diagnosticar a síndrome do ovário policístico (SOP) durante a adolescência é um desafio, uma vez que o desenvolvimento puberal normal se sobrepõe às características típicas desta síndrome. Os autores têm por objetivo resumir as evidências existentes sobre a SOP na adolescência, particularmente seus critérios diagnósticos e opções terapêuticas. Uma pesquisa em bases de dados médicas como PubMed e MedScape foi realizada. Os critérios de diagnóstico incluem ciclos menstruais irregulares de acordo com o tempo pós-menarca e evidência de hiperandrogenismo clínico e/ou hiperandrogenismo bioquímico, após exclusão de outras causas. A morfologia policística dos ovários não deve ser usada como um critério diagnóstico. O tratamento deve ser direcionado às manifestações e/ou comorbilidades, mesmo na ausência de um diagnóstico definitivo. As intervenções no estilo de vida são o tratamento de primeira linha. Contraceptivos orais combinados, metformina ou antiandrogênios também podem ser considerados como adjuvantes. O rastreamento da SOP na adolescência é fundamental, pois permite uma intervenção precoce ao nível dos sintomas e comorbilidades presentes levando a melhores resultados reprodutivos e metabólicos a longo prazo.